Last €6.10 EUR
Change Today -0.10 / -1.61%
Volume 186.0
TXCL On Other Exchanges
EN Paris
As of 10:39 AM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

txcell (TXCL) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/2/14 - €8.10
52 Week Low
10/16/14 - €4.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TXCELL (TXCL)

Related News

No related news articles were found.

txcell (TXCL) Related Businessweek News

No Related Businessweek News Found

txcell (TXCL) Details

TxCell Promesses develops cell-based immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases. The company’s product candidates include OvaSave, which has completed phase I/II clinical trials for the treatment of severe refractory Crohn’s disease; and Col-Treg, which is under preclinical stage for the treatment of autoimmune uveitis. Its other product candidates include Myelin that is under development for the treatment of central nervous system inflammatory diseases; and HSP60, which is under development for the treatment of autoimmune and inflammatory diseases. The company was formerly known as TxCell S.A. and changed its name to TxCell Promesses in April 2014. TxCell Promesses was founded in 2001 and is headquartered in Valbonne, France.

40 Employees
Last Reported Date: 10/2/14
Founded in 2001

txcell (TXCL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

txcell (TXCL) Key Developments

Txcell Reports Revenue Results for the Third Quarter and Nine Months Ended September 30, 2014

TxCell reported revenue results for the third quarter and Nine Months ended September 30, 2014. For the quarter, the company reported revenue of EUR 83,000 compared with no reported revenues during the same period in 2013. For the nine months, the company generated revenues of EUR 245,000 compared with no reported revenues during the same period in 2013.

TxCell SA Achieves Positive Results for Col-Treg in a Model of Autoimmune Uveitis

TxCell SA announced that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a cause of blindness with very limited treatment options. TxCell demonstrated clear efficacy and tolerability of Col-Treg for the treatment of autoimmune uveitis. The results generated in the model include pharmacodynamic and pharmacokinetic data that shows a reduction in the severity of uveitis on clinical and histologic measures. In addition, TxCell has also generated GLP toxicology results that indicate a good safety profile for Col-Treg. TxCell intends to submit these results for publication in a recognized, peer-reviewed journal. Autoimmune uveitis has been characterised as a disease in which there is a dysfunction of the T regulatory cell compartment of the immune system. Recent scientific studies have demonstrated that the administration or induction of regulatory T (Treg) cells in vivo can be used as therapeutic tools for the control of ocular inflammation, including that seen in autoimmune uveitis. As a result, TxCell is developing Col-Treg as a personalized T cell immunotherapy based on the regulatory properties of autologous collagen-II specific regulatory T lymphocytes. Col-Treg is specifically designed to exert a multi-target, multi-mechanism suppressive and anti-inflammatory action locally in the eye upon recognition of collagen-II, a protein present in the vitreous body of both the eye and retina. TxCell has ensured that Col-Treg will benefit from a robust manufacturing process, utilising its experience with Ovasave(R), TxCell's product for inflammatory bowel diseases. Manufacturing of Col-Treg will takes place in TxCell's own GMP accredited French manufacturing facility.

TxCell Promesses(ENXTPA:TXCL) added to CAC All-Tradable Index

TxCell Promesses will be added to the CAC All-Tradable Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TXCL:FP €6.10 EUR -0.10

TXCL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TXCL.
View Industry Companies

Industry Analysis


Industry Average

Valuation TXCL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.7x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TXCELL, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at